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Commentary
The effective management of psychotic disorders in 
the U.S. requires a focused interprofessional approach. 
Consider the way in which this group of illnesses can 
affect a person’s mind: they lead to alterations in the 
ability to think clearly, make rational judgments or de-
cisions, respond emotionally, communicate effectively, 
understand reality from imagination, and behave ap-
propriately in public (Hersen, Turner, & Beidel, 2007). 
Because of this, most modern health care systems place 
an emphasis on integrated healthcare services. These 
optimize patient care when the patient may not be the 
best historian, and reduce the likelihood of regression, 
which may often be observed with mental illness (Le-
gare, et. al., 2011).
Psychotic disorders, such as schizophrenia, by defini-
tion significantly impair an individual’s ability to stay in 
touch with reality and to meet the demands of everyday 
life. Schizophrenia and other primary psychotic con-
ditions can be chronic and can grossly impair reality, 
which can be interrupted by delusions, hallucinations, 
disorganized behavior and speech (Gearing, 2008). An 
interprofessional approach that involves the collabora-
tive efforts of psychiatry and pharmacy services can be 
vital in achieving positive therapeutic outcomes within 
an inpatient care setting (Hahn, Albers, & Reist, 2008). 
The ability to find effective methods to involve a variety 
of health care disciplines in the clinical decision-making 
process for the management of psychotic disorders can 
improve care, and yield benefits for the patient (Makoul 
& Clayman, 2006).  According to a study conducted by 
Johnson-Lawrence and colleagues (2012), performance 
of a comprehensive evaluation/assessment that a final 
diagnosis can be given to a patient with depression can 
produce greater adherence to treatment, improvement 
in symptoms, and can reduce delays in patients’ initia-
tion of treatment. 
One way to ensure compliance with anti-psychotic me-
diations is admitting the patient to an inpatient psychi-
atric facility. For patients to be admitted to an inpatient 
psychiatric facility requiring immediate psychiatric 
evaluation and stabilization, the criteria can include (1) 
imminent danger to oneself or others, (2) acute impair-
ment of ability to perform activities of daily living, (3) 
impulsive or assaultive behavior, and (4), management 
of withdrawal states (Prunier & Buongiorno, 1989). A 
patient’s first encounter may be with an attending psy-
chiatrist who works to identify the presenting problems 
in order to arrive at a diagnosis.  This is the first step in 
providing the correct treatment. Some of the differential 
diagnoses that the psychiatrist may arrive at are bipolar 
disorder, schizophrenia, delirium, or anxiety disorder, 
to name a few. Ultimately it is through the performance 
of a comprehensive evaluation/assessment  that a final 
diagnosis is not made in error (Guadiano & Zimmer-
man, 2012). 
Once a diagnosis has been made, the attending psychi-
atrist can consult with a clinical pharmacist specifically 
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trained in mental health regarding appropriate drug 
selection(s) to ensure that there is clinical justification 
for the choice of these medications. In certain cases, 
there is the potential for psychotropic polypharmacy 
to occur in an inpatient psychiatric facility.  Polyphar-
macy is defined as the use of a certain number of drugs 
to treat a condition regardless of the appropriateness of 
these drugs, even if the medications are not clinically 
indicated (Powers, 2005). Polypharmacy can be avoid-
ed by a clinical pharmacist providing assistance to the 
psychiatrist with selecting more appropriate medica-
tions if some are not warranted (Mojatabai & Olfson, 
2010). The collaboration between psychiatrists and 
pharmacists in the inpatient psychiatric setting has the 
potential to reduce the incidences of polypharmacy and 
lead to effective patient care  as a result of , 1) obtaining 
an accurate medication and physical history, 2) linking 
each prescribed medication to the psychiatric condi-
tion, 3) identifying medications that are being used to 
treat side effects, 4) initiating interventions to ensure 
medication compliance or adherence, 5) prevention by 
regularly considering the appropriateness of the medi-
cation for the condition (De las Cuevas & Sanz, 2004; 
Powers, 2005). 
The advantage of an interprofessional approach to psy-
chotropic medication management is that psychiatrists 
can offer their level of expertise in providing accurate 
diagnoses and subsequently collaborate with clinical 
pharmacists. The pharmacists can offer their drug ex-
pertise by providing recommendations for medication 
management to align with the presenting disorder. The 
goal for any form of collaboration that occurs between 
these two health professionals is to achieve the thera-
peutic endpoint of alleviating or reducing the symp-
toms that are associated with the psychotic disorder and 
optimizing treatment without increasing psychotropic 
medication utilization (Morrison, Duryea, Moore, & 
Nathanson-Shin, 2012).
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